Kite Pharma (KITE)

NASDAQ
179.79
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    179.55 - 179.95
  • 52 wk Range:
    0.00 - 0.00

KITE Overview

Prev. Close
179.79
Day's Range
179.55-179.95
Revenue
32.14M
Open
179.82
52 wk Range
0-0
EPS
-6.9
Volume
0
Market Cap
10.31B
Dividend (Yield)
0.00
(N/A)
Average Vol. (3m)
3,854,063
P/E Ratio
-
Beta
0.861
1-Year Change
0%
Shares Outstanding
57,364,623
Next Earnings Date
-
What is your sentiment on Kite Pharma?
or
Market is currently closed. Voting is open during market hours.

Kite Pharma News

Kite Pharma Analysis

Kite Pharma Company Profile

Kite Pharma Company Profile

Employees
447

Kite Pharma, Inc. focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with relapsed/refractory, as well as Phase 1b/2 clinical trial of KTE-C19 in combination with Genentech’s atezolizumab in patients with refractory DLBCL. In addition, it engages in developing T cell receptors-based therapies, which targets self-antigens, viral antigens, and neo-antigens. The company has a research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; cooperative research and development agreements with the U.S. Department of Health and Human Services; a license agreement with Cabaret Biotech Ltd. and National Institutes of Health; a license and research agreement with Alpine Immune Sciences, Inc.; a research collaboration and license agreements with Cell Design Labs, Inc., Appia Bio, Inc., and HiFiBiO Therapeutics; collaboration agreements with Gadeta B.V. and Sangamo Therapeutics, Inc.; and clinical collaboration agreement with Humanigen, Inc. and Kiniksa Pharmaceuticals, Ltd. The company was founded in 2009 and is headquartered in Santa Monica, California. As of October 2, 2017, Kite Pharma, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralStrong BuyStrong Buy
Technical IndicatorsSellSellBuyStrong BuyStrong Buy
SummaryStrong SellSellNeutralStrong BuyStrong Buy
  • Reason for the sell-off: People are gravitating to an old bad news, rather than good news. . Kite Pharma's lead product candidate shows high response rate in treatment-resistant NHL, two treatment-related death reported; shares off 4%. . Dec. 6, 2016 11:41 AM ET|About: Kite Pharma (KITE)|By: Douglas W. House, SA News Editor . Results from a pivotal Phase 1/2 clinical trial, ZUMA-1, assessing Kite Pharma's (KITE -3.7%) lead product candidate axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) showed over 3/4 of patients responded to treatment. The data were presented at the 58th American Society of Hematology (ASH) annual meeting in San Diego..
    0